Immune Response to Nebulized Phage Therapy in Cystic Fibrosis Patients Wins Best Short Oral at Phage Therapy 2024

The Targeting Phage Therapy 2024 Best Short Oral Presentation award was discerned to:

Neutralizing Antibodies After Nebulized Phage Therapy in Cystic Fibrosis Patients
Marco Pardo-Freire, University of Valencia, Spain

His research demonstrated that nebulized phage therapy significantly reduces bacterial load in Cystic Fibrosis (CF) patients with lung infections and highlighted the emergence of phage-neutralizing antibodies, emphasizing the need for long-term immune response monitoring. Learn more.

Currently, as part of his PhD, Mr. Pardo-Freire is focused on the study and understanding of micobacteriophages for use in therapy, including different species of Mycobacterium such as Mycobacterium abscessus to Mycobacterium tuberculosis, but he is also involved in the development of new compassionate use treatments with phages in Spain. 

You can learn about this inspiring finding and talk in Targeting Phage Therapy 2024 Replay and Abstracts Book.

Targeting Phage Therapy 2024 Congress
7th World Conference
June 20-21, 2024 – Malta